CMC & ManufacturingLast reviewed April 2026

Quality Target Product Profile(QTPP)

A prospective summary of the quality characteristics a drug product should possess to deliver the intended therapeutic benefit to the patient.

Usage Examples

The QTPP specified immediate release, 95% dissolution at 30 minutes, for the oral tablet.
Each CQA in the control strategy traced back to a specific QTPP element.
Changes to the target release profile required QTPP revision and cascading CMC impact assessment.

What is QTPP?

The Quality Target Product Profile (QTPP) is a foundational concept in ICH Q8 Quality by Design (QbD) drug product development. It is a prospective summary of the quality characteristics of a drug product — dosage form, route of administration, strength, container closure, release profile, stability, and key safety and efficacy attributes — that define what the product must deliver to be clinically and commercially successful.

The QTPP drives downstream CMC decisions: identification of Critical Quality Attributes (CQAs), Critical Process Parameters (CPPs), formulation development, analytical method development, and control strategy design. A well-defined QTPP ensures formulation and manufacturing development are aligned with patient-relevant product performance from the start, reducing late-stage rework.

QTPPs are patient-centric and link-based: they connect product quality attributes to patient outcomes, and each CQA should trace back to a QTPP element. QTPPs are living documents — they evolve during development as knowledge accumulates, but major changes late in development are costly because they force reassessment of the entire CMC package.

Regulatory Context

This term appears most often in cmc & manufacturing workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ICH Q8, ICH Q9, ICH Q10.

FDAICHHealth Canada

When This Matters

The QTPP specified immediate release, 95% dissolution at 30 minutes, for the oral tablet.
Each CQA in the control strategy traced back to a specific QTPP element.
Changes to the target release profile required QTPP revision and cascading CMC impact assessment.

Common Mistakes

Failing to align CMC change narratives with current CFR/ICH expectations.
Submitting incomplete control strategy documentation.
Separating manufacturing and regulatory review cycles too late in execution.

Related Regulations

ICH Q8ICH Q9ICH Q10ICH Q11

Frequently Asked Questions

The QTPP is ideally defined at the start of formulation development, informed by the target clinical profile and early nonclinical data. It evolves through development as knowledge accumulates but should be stable by the time pivotal clinical batches are manufactured — major QTPP changes during Phase 3 are expensive to propagate.

Dosage form and route of administration, strength and dosing frequency, release profile (immediate/controlled/extended), container closure system, stability requirements (shelf life, storage conditions), drug product quality attributes impacting safety or efficacy, and patient-relevant attributes like taste or ease of administration.

The QTPP defines what the product must do; CQAs define the measurable quality attributes of the drug substance or product that must be controlled to deliver the QTPP. Every CQA should trace to one or more QTPP elements, and every QTPP element should have associated CQAs that ensure it is delivered consistently.